Cutaneous malignant melanoma.

[1]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Parker,et al.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  D. Reintgen,et al.  Radioguided surgery for melanoma. , 1999, Surgical oncology clinics of North America.

[4]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. C. Johnson,et al.  Follow‐up of patients with a thin melanoma , 1999, The British journal of surgery.

[6]  S. Steinberg,et al.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Zitelli,et al.  Mohs micrographic surgery: a cost analysis. , 1998, Journal of the American Academy of Dermatology.

[8]  Zitelli Ja,et al.  Mohs Micrographic Surgery Using HMB-45 for a Recurrent Acral Melanoma , 1998 .

[9]  K. Tracey,et al.  The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[11]  J. Thompson,et al.  Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. , 1997, The cancer journal from Scientific American.

[12]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Reintgen,et al.  The Role of Research in Cost Containment. , 1995, Cancer control : journal of the Moffitt Cancer Center.

[14]  D. Fraker,et al.  Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. , 1995, The cancer journal from Scientific American.

[15]  M. Ross,et al.  The Orderly Progression of Melanoma Nodal Metastases , 1994, Annals of surgery.

[16]  M. Ross,et al.  Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. , 1993, Seminars in surgical oncology.

[17]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[18]  M. Atkins,et al.  Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Cascinelli,et al.  Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. , 1991, Archives of surgery.

[20]  D. Goldberg,et al.  Mohs micrographic surgery. , 2012, Clinical privilege white paper.

[21]  C. Balch,et al.  Thin Stage I Primary Cutaneous Malignant Melanoma , 1988 .

[22]  C. Karakousis,et al.  Early metastatic patterns and survival in malignant melanoma , 1987, Journal of surgical oncology.

[23]  C. Karakousis,et al.  Effect of surgical treatment on stage IV melanoma. , 1987, American journal of surgery.

[24]  A. Luini,et al.  Distribution of axillary node metastases by level of invasion. An analysis of 539 cases , 1987, Cancer.

[25]  C. Balch,et al.  Surgery as Palliative Treatment for Distant Metastases of Melanoma , 1986, Annals of surgery.

[26]  M. Shiu,et al.  Surgical treatment of distant metastatic melanoma indications and results , 1985, Cancer.

[27]  W. McCarthy,et al.  Resection margins for melanoma. , 1985, Australian and New Zealand Journal of Surgery.

[28]  M. S. Blois,et al.  The Frequency of Local Recurrence and Microsatellites as a Guide to Reexcision Margins for Cutaneous Malignant Melanoma , 1984, Annals of surgery.

[29]  J. Müller,et al.  A Prospective Randomized Study of Regional Extremity Perfusion in Patients with Malignant Melanoma , 1984, Annals of surgery.

[30]  M. Mihm,et al.  Conservative surgical management of superficially invasive cutaneous melanoma , 1984, Cancer.

[31]  A. Kopf,et al.  Local and In‐Transit Metastases Following Definitive Excision for Primary Cutaneous Malignant Melanoma , 1983, Annals of surgery.

[32]  O. Braun-falco,et al.  Low- and high-risk malignant melanoma--II. Multivariate analyses for a prognostic classification. , 1983, European journal of cancer & clinical oncology.

[33]  C. Balch,et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  W. Clark,et al.  Optimal Resection Margin for Cutaneous Malignant Melanoma , 1983, Plastic and reconstructive surgery.

[35]  R. Benjamin,et al.  The natural history of resectable metastatic melanoma (Stage IVA Melanoma) , 1982, Cancer.

[36]  M. Mihm,et al.  Narrower margins for clinical stage I malignant melanoma. , 1982, The New England journal of medicine.

[37]  B. Cady,et al.  Changes in clinical presentation and management of malignant melanoma , 1981, Cancer.

[38]  W. McCarthy,et al.  Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I) , 1980, The British journal of surgery.

[39]  C. Balch,et al.  Tumor thickness as a guide to surgical management of clinical stage I melanoma patients , 1979, Cancer.

[40]  A. Breslow,et al.  Optimal size of resection margin for thin cutaneous melanoma. , 1977, Surgery, gynecology & obstetrics.

[41]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[42]  O. Verola,et al.  Le mélanome malin , 1998 .

[43]  C W Cruse,et al.  Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. , 1996, Annals of surgery.

[44]  M. Mihm,et al.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. , 1993, Annals of surgery.

[45]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Ackerman.  MALIGNANT MELANOMA IN SITU: THE FLAT, CURABLE STAGE OF MALIGNANT MELANOMA , 1985, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[47]  A. Ackerman.  Pathology of malignant melanoma , 1981 .